293 related articles for article (PubMed ID: 31856868)
1. Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer.
Fernandez-Garcia D; Hills A; Page K; Hastings RK; Toghill B; Goddard KS; Ion C; Ogle O; Boydell AR; Gleason K; Rutherford M; Lim A; Guttery DS; Coombes RC; Shaw JA
Breast Cancer Res; 2019 Dec; 21(1):149. PubMed ID: 31856868
[TBL] [Abstract][Full Text] [Related]
2. Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts.
Shaw JA; Guttery DS; Hills A; Fernandez-Garcia D; Page K; Rosales BM; Goddard KS; Hastings RK; Luo J; Ogle O; Woodley L; Ali S; Stebbing J; Coombes RC
Clin Cancer Res; 2017 Jan; 23(1):88-96. PubMed ID: 27334837
[TBL] [Abstract][Full Text] [Related]
3. Integrative statistical analyses of multiple liquid biopsy analytes in metastatic breast cancer.
Keup C; Suryaprakash V; Hauch S; Storbeck M; Hahn P; Sprenger-Haussels M; Kolberg HC; Tewes M; Hoffmann O; Kimmig R; Kasimir-Bauer S
Genome Med; 2021 May; 13(1):85. PubMed ID: 34001236
[TBL] [Abstract][Full Text] [Related]
4. c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.
Park J; Chang ES; Kim JY; Chelakkot C; Sung M; Song JY; Jung K; Lee JH; Choi JY; Kim NY; Lee H; Kang MR; Kwon MJ; Shin YK; Park YH; Choi YL
Breast Cancer Res; 2024 Jan; 26(1):13. PubMed ID: 38238761
[TBL] [Abstract][Full Text] [Related]
5. Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer.
Rossi G; Mu Z; Rademaker AW; Austin LK; Strickland KS; Costa RLB; Nagy RJ; Zagonel V; Taxter TJ; Behdad A; Wehbe FH; Platanias LC; Gradishar WJ; Cristofanilli M
Clin Cancer Res; 2018 Feb; 24(3):560-568. PubMed ID: 29180605
[No Abstract] [Full Text] [Related]
6. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903
[TBL] [Abstract][Full Text] [Related]
7. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.
Bidard FC; Peeters DJ; Fehm T; Nolé F; Gisbert-Criado R; Mavroudis D; Grisanti S; Generali D; Garcia-Saenz JA; Stebbing J; Caldas C; Gazzaniga P; Manso L; Zamarchi R; de Lascoiti AF; De Mattos-Arruda L; Ignatiadis M; Lebofsky R; van Laere SJ; Meier-Stiegen F; Sandri MT; Vidal-Martinez J; Politaki E; Consoli F; Bottini A; Diaz-Rubio E; Krell J; Dawson SJ; Raimondi C; Rutten A; Janni W; Munzone E; Carañana V; Agelaki S; Almici C; Dirix L; Solomayer EF; Zorzino L; Johannes H; Reis-Filho JS; Pantel K; Pierga JY; Michiels S
Lancet Oncol; 2014 Apr; 15(4):406-14. PubMed ID: 24636208
[TBL] [Abstract][Full Text] [Related]
8. Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients.
Kohli M; Li J; Du M; Hillman DW; Dehm SM; Tan W; Carlson R; Campion MB; Wang L; Wang L; Zhang H; Zhang P; Kilari D; Huang CC; Wang L
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):411-418. PubMed ID: 29858592
[TBL] [Abstract][Full Text] [Related]
9. Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA.
Ye Z; Wang C; Wan S; Mu Z; Zhang Z; Abu-Khalaf MM; Fellin FM; Silver DP; Neupane M; Jaslow RJ; Bhattacharya S; Tsangaris TN; Chervoneva I; Berger A; Austin L; Palazzo JP; Myers RE; Pancholy N; Toorkey D; Yao K; Krall M; Li X; Chen X; Fu X; Xing J; Hou L; Wei Q; Li B; Cristofanilli M; Yang H
Eur J Cancer; 2019 Jan; 106():133-143. PubMed ID: 30528798
[TBL] [Abstract][Full Text] [Related]
10. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
[TBL] [Abstract][Full Text] [Related]
11. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
[TBL] [Abstract][Full Text] [Related]
12. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M
BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
15. Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes.
Peeters DJ; van Dam PJ; Van den Eynden GG; Rutten A; Wuyts H; Pouillon L; Peeters M; Pauwels P; Van Laere SJ; van Dam PA; Vermeulen PB; Dirix LY
Br J Cancer; 2014 Jan; 110(2):375-83. PubMed ID: 24366294
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and Predictive Value of Circulating and Disseminated Tumor Cells in Breast Cancer: A National Cancer Database (NCDB) Analysis.
Bilani N; Elson L; Liang H; Elimimian EB; Arteta-Bulos R; Nahleh Z
Technol Cancer Res Treat; 2020; 19():1533033820980107. PubMed ID: 33287661
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.
Müller V; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer E; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T;
Breast Cancer Res; 2012 Aug; 14(4):R118. PubMed ID: 22894854
[TBL] [Abstract][Full Text] [Related]
18. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer.
Wang C; Mu Z; Chervoneva I; Austin L; Ye Z; Rossi G; Palazzo JP; Sun C; Abu-Khalaf M; Myers RE; Zhu Z; Ba Y; Li B; Hou L; Cristofanilli M; Yang H
Breast Cancer Res Treat; 2017 Jan; 161(1):83-94. PubMed ID: 27771841
[TBL] [Abstract][Full Text] [Related]
19. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
[TBL] [Abstract][Full Text] [Related]
20. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
